Sector Alpha Week of 2026-08-05
20-quarter listed-company comparison

Diagnostics Stocks in India

Diagnostics: Dr Lal Pathlabs Ltd owns the largest revenue base; One Global Service Provider Ltd has the fastest current growth.

01 · the index people search for

Nifty Diagnostics Index — Constituents & Performance

The Diagnostics companies below are the listed Indian Diagnostics universe this page tracks — the same constituent set people search for as the Nifty Diagnostics index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.

02 · the sector itself · before any single company

How has Diagnostics moved against NIFTY 500?

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this sector is 82% ahead of NIFTY 500. Earnings across its companies grew 22% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 13 weeks running.

LEADER · ahead 13w✓Price and the fundamentals both up5 of 9 companies ahead of NIFTY 500 by 5% or more over three months2 are 20% or more behind over a year while earnings grew 20% or more

RS ↑13w · 6/9 >200d (+0) · 5/9 lead (−1) · EPS 8/9↑

20050020262025202420232022 746333 TRAILING 12-MONTH EPS · 100 AT THE START0100170Sep 22Mar 23Sep 23Mar 24Sep 24Mar 25Sep 25Mar 26Jun 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 4 reporting · thin coverageSep 2022 · trailing 12-month earnings per share at 91, against 100 at the start · no comparable year yet · 5 reportingDec 2022 · trailing 12-month earnings per share at 87, against 100 at the start · no comparable year yet · 5 reportingMar 2023 · trailing 12-month earnings per share at 88, against 100 at the start · no comparable year yet · 5 reportingJun 2023 · trailing 12-month earnings per share at 97, against 100 at the start · down 11.7% on a year ago · 5 reportingSep 2023 · trailing 12-month earnings per share at 100, against 100 at the start · down 13.8% on a year ago · 7 reportingDec 2023 · trailing 12-month earnings per share at 98, against 100 at the start · down 12.9% on a year ago · 7 reportingMar 2024 · trailing 12-month earnings per share at 97, against 100 at the start · up 2.4% on a year ago · 7 reportingJun 2024 · trailing 12-month earnings per share at 101, against 100 at the start · up 20.0% on a year ago · 8 reportingSep 2024 · trailing 12-month earnings per share at 110, against 100 at the start · up 28.7% on a year ago · 8 reportingDec 2024 · trailing 12-month earnings per share at 127, against 100 at the start · up 31.7% on a year ago · 8 reportingMar 2025 · trailing 12-month earnings per share at 131, against 100 at the start · up 34.8% on a year ago · 7 reportingJun 2025 · trailing 12-month earnings per share at 135, against 100 at the start · up 31.4% on a year ago · 7 reportingSep 2025 · trailing 12-month earnings per share at 142, against 100 at the start · up 18.0% on a year ago · 7 reportingDec 2025 · trailing 12-month earnings per share at 135, against 100 at the start · up 15.9% on a year ago · 7 reportingMar 2026 · trailing 12-month earnings per share at 170, against 100 at the start · up 23.1% on a year ago · 7 reportingNot reported yet — earnings trail price by a quarter or two170 · Mar 26No earnings on file this far back — the price series reaches further than the filings doNO EARNINGS ON FILE
20050020262025202420232022 746333 TRAILING 12-MONTH EPS · 100 AT THE START0100170Mar 23Mar 24Mar 25Mar 26Jun 2022 · trailing 12-month earnings per share at 100, against 100 at the start · no comparable year yet · 4 reporting · thin coverageSep 2022 · trailing 12-month earnings per share at 91, against 100 at the start · no comparable year yet · 5 reportingDec 2022 · trailing 12-month earnings per share at 87, against 100 at the start · no comparable year yet · 5 reportingMar 2023 · trailing 12-month earnings per share at 88, against 100 at the start · no comparable year yet · 5 reportingJun 2023 · trailing 12-month earnings per share at 97, against 100 at the start · down 11.7% on a year ago · 5 reportingSep 2023 · trailing 12-month earnings per share at 100, against 100 at the start · down 13.8% on a year ago · 7 reportingDec 2023 · trailing 12-month earnings per share at 98, against 100 at the start · down 12.9% on a year ago · 7 reportingMar 2024 · trailing 12-month earnings per share at 97, against 100 at the start · up 2.4% on a year ago · 7 reportingJun 2024 · trailing 12-month earnings per share at 101, against 100 at the start · up 20.0% on a year ago · 8 reportingSep 2024 · trailing 12-month earnings per share at 110, against 100 at the start · up 28.7% on a year ago · 8 reportingDec 2024 · trailing 12-month earnings per share at 127, against 100 at the start · up 31.7% on a year ago · 8 reportingMar 2025 · trailing 12-month earnings per share at 131, against 100 at the start · up 34.8% on a year ago · 7 reportingJun 2025 · trailing 12-month earnings per share at 135, against 100 at the start · up 31.4% on a year ago · 7 reportingSep 2025 · trailing 12-month earnings per share at 142, against 100 at the start · up 18.0% on a year ago · 7 reportingDec 2025 · trailing 12-month earnings per share at 135, against 100 at the start · up 15.9% on a year ago · 7 reportingMar 2026 · trailing 12-month earnings per share at 170, against 100 at the start · up 23.1% on a year ago · 7 reportingNot reported yet — earnings trail price by a quarter or two170No earnings on file this far back — the price series reaches further than the filings do
Diagnostics, equal-weighted, based at 200 NIFTY 500, same base, same start trailing 12-month earnings per share rising falling

Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 9 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.

03 · sector relative strength, before individual stocks

Is Diagnostics outperforming NIFTY 500?

Diagnostics has outperformed NIFTY 500 by 10.9% over the last 52 weeks. Over 13 weeks the gap is a lead of 15.5%. 6 of 9 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Thyrocare Technologies Ltd is the strongest against the sector itself at +16.8%. Readings are as of 2026-07-19.

+15.5%Sector vs NIFTY 500 · 13 weeks
+10.9%Sector vs NIFTY 500 · 52 weeks
6/9Stocks leading NIFTY 500
5/9Stocks leading sector

Sector metric: 23.2 as of 2026-07-19 · CONSOLIDATION · falling.

The central tension: the companies with the most scale are not necessarily the companies creating the most change.

Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.

Bottom line

Diagnostics has outperformed NIFTY 500 by 10.9% over 52 weeks and 15.5% over 13 weeks. 6 of 9 covered companies beat NIFTY on Mansfield relative strength, while 5 of 9 beat the sector itself. Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 9 of 9 comparable companies through Jun 2026.

Companies
9
complete canonical membership
Combined market value
₹75.0K Cr
Dr Lal Pathlabs Ltd
Revenue growing
9/9
positive TTM year-on-year growth
Beating NIFTY 500
6/9
positive Mansfield relative strength
Comparing 5 of 9
04 · research priority, made explicit

4-Factor Sector Score

An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.

Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Thyrocare Technologies Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 100% evidence confidence.
Dr Lal Pathlabs Ltd looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
Dr Lal Pathlabs Ltd has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
How this score is built, and what the marks mean

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Thyrocare Technologies LtdTHYROCARE 77.4/100Favorable setup100% evidence LEADER 27.9/35 Revenue 21.3% · PAT 67.6% · OPM change 2 pp 100% evidence 18.1/25 ROCE 35.4% · OPM 32% 100% evidence 12.0/20 P/E 51× · PEG 1.1 100% evidence 19.4/20 RS sector 16.8% · RS bench 27.8% · 1Y 32.4%12 of 12 weeks ahead 100% evidence
Exact sum: 27.9 + 18.1 + 12 + 19.4 = 77.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.
2Dr Lal Pathlabs LtdLALPATHLAB 63.3/100Mixed-positive evidence100% evidence LEADER 14.6/35 Revenue 14.3% · PAT 5% · OPM change 2 pp 100% evidence 16.8/25 ROCE 28% · OPM 31% 100% evidence 13.0/20 P/E 56.8× · PEG 1.29 100% evidence 18.9/20 RS sector 11.6% · RS bench 22.5% · 1Y 23.8%12 of 12 weeks ahead 100% evidence
Exact sum: 14.6 + 16.8 + 13 + 18.9 = 63.3 · Decision use: Price leads the evidence: RS versus the benchmark is 22.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
3Metropolis Healthcare LtdMETROPOLIS 60.1/100Mixed-positive evidence96% evidence LEADER 27.2/35 Revenue 23.7% · PAT 31.7% · OPM change 7 pp 88% evidence 11.7/25 ROCE 17.8% · OPM 25% 100% evidence 6.3/20 P/E 62.3× · PEG 2.4 100% evidence 14.9/20 RS sector 4.3% · RS bench 14.4% · 1Y 18.3%12 of 12 weeks ahead 100% evidence
Exact sum: 27.2 + 11.7 + 6.3 + 14.9 = 60.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4One Global Service Provider Ltd514330 59.8/100Mixed-positive evidence78% evidence TURNING 24.9/35 Revenue 100% · PAT 100% · OPM change -8 pp 83% evidence 16.5/25 ROCE 87% · OPM 18% 76% evidence 10.1/20 P/E 15.9× · PEG — 50% evidence 8.3/20 RS sector 1.3% · RS bench 10.9% · 1Y 121.4%2 of 12 weeks ahead 100% evidence
Exact sum: 24.9 + 16.5 + 10.1 + 8.3 = 59.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Vijaya Diagnostic Centre LtdVIJAYA 58.8/100Mixed-positive evidence96% evidence LEADER 20.1/35 Revenue 19.5% · PAT 20.1% · OPM change 4 pp 88% evidence 18.5/25 ROCE 21.3% · OPM 44% 100% evidence 6.4/20 P/E 80× · PEG 1.46 100% evidence 13.8/20 RS sector 11.3% · RS bench 21.8% · 1Y 25.6%12 of 12 weeks ahead 100% evidence
Exact sum: 20.1 + 18.5 + 6.4 + 13.8 = 58.8 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression.
63B Blackbio DX Ltd3BBLACKBIO 48.6/100Mixed-negative evidence83% evidence TURNING 15.2/35 Revenue 47.1% · PAT 25.7% · OPM change -11.2 pp 83% evidence 15.8/25 ROCE 25.5% · OPM 24% 95% evidence 11.8/20 P/E 18.3× · PEG — 50% evidence 5.8/20 RS sector -17.6% · RS bench -9.3% · 1Y -13.2%0 of 12 weeks ahead 100% evidence
Exact sum: 15.2 + 15.8 + 11.8 + 5.8 = 48.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Krsnaa Diagnostics LtdKRSNAA 43.0/100Mixed-negative evidence77% evidence ASLEEP 13.4/35 Revenue 7.8% · PAT 30.8% · OPM change 0 pp 83% evidence 10.5/25 ROCE 12.7% · OPM 28% 95% evidence 14.6/20 P/E 16.9× · PEG — 50% evidence 4.5/20 RS sector -18.5% · RS bench -23.4% · 1Y -38.1%0 of 10 weeks ahead 70% evidence
Exact sum: 13.4 + 10.5 + 14.6 + 4.5 = 43 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
8Suraksha Diagnostic LtdSURAKSHA 39.0/100Mixed-negative evidence76% evidence ASLEEP 13.8/35 Revenue 23.1% · PAT 1.4% · OPM change 0.5 pp 83% evidence 13.0/25 ROCE 17% · OPM 29.9% 95% evidence 10.4/20 P/E 40.8× · PEG — 15% evidence 1.8/20 RS sector -20.4% · RS bench -12.3% · 1Y -17.8%4 of 12 weeks ahead 100% evidence
Exact sum: 13.8 + 13 + 10.4 + 1.8 = 39 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
9Vimta Labs LtdVIMTALABS 44.4/100Thin evidence · provisional45% evidence TURNING 17.5/35 Revenue 7.8% · PAT 48.8% · OPM change 5 pp 18% evidence 13.5/25 ROCE 17.6% · OPM 37% 57% evidence 7.5/20 P/E 44.8× · PEG — 50% evidence 5.9/20 RS sector -21.9% · RS bench 4.8% · 1Y 4.1%7 of 10 weeks ahead 70% evidence
Exact sum: 17.5 + 13.5 + 7.5 + 5.9 = 44.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
05 · what price has already done

Market action

One Global Service Provider Ltd has the strongest one-year price move in Diagnostics at +121.4%. Thyrocare Technologies Ltd leads on Mansfield relative strength against NIFTY at +27.8%. 6 of 9 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-31.

Price and relative strength

Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

06 · compare level, then change

Revenue Scale & Growth Durability

Dr Lal Pathlabs Ltd has the highest Revenue among the 9 Diagnostics companies compared here, at ₹2,892 crore. Metropolis Healthcare Ltd is next at ₹1,646 crore. One Global Service Provider Ltd has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Dr Lal Pathlabs Ltd is the scale leader at ₹2,892 crore, 75.7% ahead of Metropolis Healthcare Ltd. One Global Service Provider Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 311.6% from a ₹498 crore base, with 15 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.

LeaderDr Lal Pathlabs Ltd · ₹2,892 crore
Gap75.7% versus #2 · Metropolis Healthcare Ltd
Persistence8/8 recent comparable periods
Coverage9/9 companies · 145 observations

Investor read: Dr Lal Pathlabs Ltd is the scale benchmark; One Global Service Provider Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.

This conclusion weakens if: Dr Lal Pathlabs Ltd's growth falls below One Global Service Provider Ltd's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Dr Lal Pathlabs Ltd LALPATHLAB₹2.9K Cr
2Metropolis Healthcare Ltd METROPOLIS₹1.6K Cr
3Thyrocare Technologies Ltd THYROCARE₹877 Cr
4Vijaya Diagnostic Centre Ltd VIJAYA₹814 Cr
5Krsnaa Diagnostics Ltd KRSNAA⚠ unverified₹773 Cr
Revenue growthfastest growers
1One Global Service Provider Ltd 514330100%
23B Blackbio DX Ltd 3BBLACKBIO⚠ unverified47%
3Metropolis Healthcare Ltd METROPOLIS24%
4Suraksha Diagnostic Ltd SURAKSHA⚠ unverified23%
5Thyrocare Technologies Ltd THYROCARE21%
Revenue · company comparison
9/9 level · 9/9 change

On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

CompanyRevenueRevenue growthReported
Dr Lal Pathlabs Ltd LALPATHLAB₹798 Cr19%Jun 2026
Metropolis Healthcare Ltd METROPOLIS₹425 Cr23%Mar 2026
Thyrocare Technologies Ltd THYROCARE₹240 Cr24%Jun 2026
Vijaya Diagnostic Centre Ltd VIJAYA₹219 Cr27%Mar 2026
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified₹193 Cr3.8%Mar 2026
One Global Service Provider Ltd 514330₹134 Cr144%Mar 2026
Vimta Labs Ltd VIMTALABS₹90 Cr20%Dec 2024
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified₹81 Cr25%Mar 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified₹35 Cr57%Mar 2026
Full 20-quarter history · every available company

Revenue · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

—
—
—
—
—
₹15 Cr
₹18 Cr
₹14 Cr
₹19 Cr
₹18 Cr
₹23 Cr
₹19 Cr
₹29 Cr
₹25 Cr
₹23 Cr
₹22 Cr
₹34 Cr
₹50 Cr
₹35 Cr
—

Dr Lal Pathlabs Ltd · LALPATHLAB

₹498 Cr
₹497 Cr
₹486 Cr
₹503 Cr
₹534 Cr
₹489 Cr
₹491 Cr
₹541 Cr
₹601 Cr
₹539 Cr
₹545 Cr
₹602 Cr
₹660 Cr
₹597 Cr
₹603 Cr
₹670 Cr
₹731 Cr
₹660 Cr
₹703 Cr
₹798 Cr

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

—
—
—
—
—
₹118 Cr
₹133 Cr
₹140 Cr
₹155 Cr
₹158 Cr
₹166 Cr
₹170 Cr
₹186 Cr
₹175 Cr
₹186 Cr
₹193 Cr
₹206 Cr
₹181 Cr
₹193 Cr
—

Metropolis Healthcare Ltd · METROPOLIS

₹303 Cr
₹293 Cr
₹306 Cr
₹280 Cr
₹300 Cr
₹285 Cr
₹283 Cr
₹277 Cr
₹308 Cr
₹291 Cr
₹331 Cr
₹313 Cr
₹350 Cr
₹323 Cr
₹345 Cr
₹386 Cr
₹429 Cr
₹406 Cr
₹425 Cr
—

One Global Service Provider Ltd · 514330

—
—
—
—
₹3 Cr
₹8 Cr
₹5 Cr
₹13 Cr
₹12 Cr
₹15 Cr
₹24 Cr
₹14 Cr
₹19 Cr
₹33 Cr
₹55 Cr
₹88 Cr
₹135 Cr
₹141 Cr
₹134 Cr
—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

—
—
—
—
—
—
—
—
₹60 Cr
₹52 Cr
₹55 Cr
₹61 Cr
₹67 Cr
₹60 Cr
₹65 Cr
₹73 Cr
₹79 Cr
₹78 Cr
₹81 Cr
—

Thyrocare Technologies Ltd · THYROCARE

₹176 Cr
₹117 Cr
₹131 Cr
₹128 Cr
₹135 Cr
₹128 Cr
₹136 Cr
₹135 Cr
₹148 Cr
₹135 Cr
₹154 Cr
₹157 Cr
₹177 Cr
₹166 Cr
₹187 Cr
₹193 Cr
₹217 Cr
₹196 Cr
₹224 Cr
₹240 Cr

Vijaya Diagnostic Centre Ltd · VIJAYA

₹113 Cr
₹111 Cr
₹116 Cr
₹104 Cr
₹121 Cr
₹113 Cr
₹121 Cr
₹121 Cr
₹139 Cr
₹133 Cr
₹155 Cr
₹156 Cr
₹183 Cr
₹169 Cr
₹173 Cr
₹188 Cr
₹202 Cr
₹205 Cr
₹219 Cr
—

Vimta Labs Ltd · VIMTALABS

—
₹67 Cr
₹74 Cr
₹79 Cr
₹80 Cr
₹77 Cr
₹82 Cr
₹83 Cr
₹66 Cr
₹75 Cr
₹80 Cr
₹75 Cr
₹85 Cr
₹90 Cr
—
—
—
—
—
—

Revenue growth · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

—
—
—
—
—
—
—
—
—
18%
27%
36%
52%
44%
-2.2%
14%
16%
98%
57%
—

Dr Lal Pathlabs Ltd · LALPATHLAB

—
—
—
-17%
7.2%
-1.6%
1.0%
7.6%
13%
10%
11%
11%
9.8%
11%
11%
11%
11%
11%
17%
19%

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

—
—
—
—
—
—
—
—
—
34%
25%
21%
20%
11%
12%
14%
11%
3.4%
3.8%
—

Metropolis Healthcare Ltd · METROPOLIS

—
—
—
-14%
-1.0%
-2.7%
-7.5%
-1.1%
2.7%
2.1%
17%
13%
14%
11%
4.2%
23%
23%
26%
23%
—

One Global Service Provider Ltd · 514330

—
—
—
—
—
—
—
—
300%
88%
380%
7.7%
58%
120%
129%
529%
611%
327%
144%
—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

—
—
—
—
—
—
—
—
—
—
—
—
11%
15%
18%
20%
18%
31%
25%
—

Thyrocare Technologies Ltd · THYROCARE

—
—
—
-22%
-23%
9.4%
3.8%
5.5%
9.6%
5.5%
13%
16%
20%
23%
21%
23%
23%
18%
20%
24%

Vijaya Diagnostic Centre Ltd · VIJAYA

—
—
—
-15%
7.1%
1.8%
4.3%
16%
15%
18%
28%
29%
32%
27%
12%
21%
10%
21%
27%
—

Vimta Labs Ltd · VIMTALABS

—
—
—
—
—
15%
11%
5.1%
-18%
-2.6%
-2.4%
-9.6%
29%
20%
—
—
—
—
—
—
07 · compare level, then change

Operating Economics & Margin Trend

Vijaya Diagnostic Centre Ltd has the highest OPM among the 9 Diagnostics companies compared here, at 44%. Vimta Labs Ltd is next at 37%. Metropolis Healthcare Ltd has the highest Margin change at +7 percentage points, so level and change sit with different companies. 9 of 9 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: Vijaya Diagnostic Centre Ltd leads opm at 44%; Metropolis Healthcare Ltd leads margin change at +7 percentage points.

LeaderVijaya Diagnostic Centre Ltd · 44%
Gap18.9% versus #2 · Vimta Labs Ltd
Persistence4/8 recent comparable periods
Coverage9/9 companies · 160 observations

Investor read: Vijaya Diagnostic Centre Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Vijaya Diagnostic Centre Ltd VIJAYA44%
2Vimta Labs Ltd VIMTALABS · older report37%
3Thyrocare Technologies Ltd THYROCARE32%
4Dr Lal Pathlabs Ltd LALPATHLAB31%
5Suraksha Diagnostic Ltd SURAKSHA⚠ unverified30%
Margin changefastest expanders
1Metropolis Healthcare Ltd METROPOLIS+7.0 pp
2Vimta Labs Ltd VIMTALABS · older report+5.0 pp
3Vijaya Diagnostic Centre Ltd VIJAYA+4.0 pp
4Dr Lal Pathlabs Ltd LALPATHLAB+2.0 pp
5Thyrocare Technologies Ltd THYROCARE+2.0 pp
Operating margin · company comparison
9/9 level · 9/9 change
All-company data · latest reported quarter
CompanyOPMMargin changeReported
Vijaya Diagnostic Centre Ltd VIJAYA44%+4.0 ppMar 2026
Vimta Labs Ltd VIMTALABS37%+5.0 ppDec 2024
Thyrocare Technologies Ltd THYROCARE32%+2.0 ppJun 2026
Dr Lal Pathlabs Ltd LALPATHLAB31%+2.0 ppJun 2026
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified30%+0.5 ppMar 2026
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified28%0.0 ppMar 2026
Metropolis Healthcare Ltd METROPOLIS25%+7.0 ppMar 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified24%−11.2 ppMar 2026
One Global Service Provider Ltd 51433018%−8.0 ppMar 2026
Full 20-quarter history · every available company

OPM · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

39%
49%
32%
44%
53%
50%
41%
45%
41%
50%
43%
56%
55%
59%
35%
53%
43%
43%
24%
—

Dr Lal Pathlabs Ltd · LALPATHLAB

28%
22%
25%
23%
27%
23%
24%
27%
30%
26%
27%
28%
31%
26%
28%
29%
31%
27%
27%
31%

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

29%
28%
26%
25%
25%
25%
26%
22%
20%
24%
26%
25%
27%
26%
28%
27%
29%
26%
28%
—

Metropolis Healthcare Ltd · METROPOLIS

30%
26%
24%
24%
26%
25%
25%
23%
24%
22%
24%
25%
26%
22%
18%
23%
25%
23%
25%
—

One Global Service Provider Ltd · 514330

21%
32%
33%
9.1%
9.0%
9.0%
10%
11%
8.0%
14%
22%
17%
16%
14%
26%
15%
19%
21%
18%
—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

—
—
—
—
—
—
—
—
35%
30%
35%
34%
35%
31%
29%
33%
31%
30%
30%
—

Thyrocare Technologies Ltd · THYROCARE

51%
31%
29%
28%
23%
22%
18%
26%
25%
23%
22%
27%
27%
25%
30%
30%
33%
30%
34%
32%

Vijaya Diagnostic Centre Ltd · VIJAYA

45%
43%
41%
38%
40%
39%
41%
40%
41%
39%
41%
39%
42%
40%
40%
39%
41%
42%
44%
—

Vimta Labs Ltd · VIMTALABS

26%
31%
31%
30%
32%
28%
30%
30%
27%
32%
31%
35%
35%
37%
—
—
—
—
—
—

Margin change · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

−31.7 pp
−10.0 pp
−12.9 pp
−11.4 pp
+13.6 pp
+1.5 pp
+9.0 pp
+0.8 pp
−12.4 pp
+0.2 pp
+1.8 pp
+11.3 pp
+14.9 pp
+9.2 pp
−7.8 pp
−3.1 pp
−12.0 pp
−16.2 pp
−11.2 pp
—

Dr Lal Pathlabs Ltd · LALPATHLAB

−1.1 pp
−8.7 pp
−3.4 pp
−7.8 pp
−1.5 pp
+1.0 pp
−0.9 pp
+3.6 pp
+3.1 pp
+3.0 pp
+3.0 pp
+1.0 pp
+1.0 pp
0.0 pp
+1.0 pp
+1.0 pp
0.0 pp
+1.0 pp
−1.0 pp
+2.0 pp

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

+1.0 pp
+9.1 pp
−8.8 pp
−6.7 pp
−4.6 pp
−3.2 pp
+0.1 pp
−2.6 pp
−4.9 pp
−1.0 pp
0.0 pp
+3.0 pp
+7.0 pp
+2.0 pp
+2.0 pp
+2.0 pp
+2.0 pp
0.0 pp
0.0 pp
—

Metropolis Healthcare Ltd · METROPOLIS

−1.7 pp
−5.8 pp
−8.6 pp
−6.9 pp
−3.5 pp
−0.7 pp
+0.5 pp
−1.5 pp
−2.3 pp
−3.0 pp
−1.0 pp
+2.0 pp
+2.0 pp
0.0 pp
−6.0 pp
−2.0 pp
−1.0 pp
+1.0 pp
+7.0 pp
—

One Global Service Provider Ltd · 514330

−75.7 pp
−32.1 pp
−29.0 pp
−0.8 pp
−12.0 pp
−23.4 pp
−22.8 pp
+1.9 pp
−1.0 pp
+5.0 pp
+12.0 pp
+6.0 pp
+8.0 pp
0.0 pp
+4.0 pp
−2.0 pp
+3.0 pp
+7.0 pp
−8.0 pp
—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

—
—
—
—
—
—
—
—
—
—
—
—
+0.1 pp
+1.1 pp
−5.8 pp
−1.2 pp
−4.1 pp
−0.9 pp
+0.5 pp
—

Thyrocare Technologies Ltd · THYROCARE

+10.2 pp
−4.7 pp
−6.3 pp
−15.0 pp
−27.2 pp
−9.2 pp
−10.8 pp
−2.1 pp
+1.6 pp
+1.0 pp
+4.0 pp
+1.0 pp
+2.0 pp
+2.0 pp
+8.0 pp
+3.0 pp
+6.0 pp
+5.0 pp
+4.0 pp
+2.0 pp

Vijaya Diagnostic Centre Ltd · VIJAYA

+0.1 pp
−3.3 pp
−7.4 pp
−8.1 pp
−5.0 pp
−4.2 pp
−0.2 pp
+1.8 pp
+0.6 pp
0.0 pp
0.0 pp
−1.0 pp
+1.0 pp
+1.0 pp
−1.0 pp
0.0 pp
−1.0 pp
+2.0 pp
+4.0 pp
—

Vimta Labs Ltd · VIMTALABS

−0.5 pp
+2.6 pp
+3.1 pp
+2.8 pp
+5.6 pp
−3.0 pp
−1.0 pp
0.0 pp
−5.0 pp
+4.0 pp
+1.0 pp
+5.0 pp
+8.0 pp
+5.0 pp
—
—
—
—
—
—
08 · compare level, then change

Profit Scale & Acceleration

Dr Lal Pathlabs Ltd has the highest Net profit among the 9 Diagnostics companies compared here, at ₹545 crore. Metropolis Healthcare Ltd is next at ₹191 crore. One Global Service Provider Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Dr Lal Pathlabs Ltd leads with ₹545 crore of TTM profit, 185.3% above Metropolis Healthcare Ltd. One Global Service Provider Ltd shows ≥100% on the scoring scale (288.9% uncapped) growth from a ₹70 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.

LeaderDr Lal Pathlabs Ltd · ₹545 crore
Gap185.3% versus #2 · Metropolis Healthcare Ltd
Persistence6/8 recent comparable periods
Coverage9/9 companies · 145 observations

Investor read: Dr Lal Pathlabs Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Dr Lal Pathlabs Ltd LALPATHLAB₹545 Cr
2Metropolis Healthcare Ltd METROPOLIS₹191 Cr
3Thyrocare Technologies Ltd THYROCARE₹176 Cr
4Vijaya Diagnostic Centre Ltd VIJAYA₹173 Cr
5Krsnaa Diagnostics Ltd KRSNAA⚠ unverified₹102 Cr
Profit growthfastest growers
1One Global Service Provider Ltd 514330100%
2Thyrocare Technologies Ltd THYROCARE68%
3Vimta Labs Ltd VIMTALABS · older report49%
4Metropolis Healthcare Ltd METROPOLIS32%
5Krsnaa Diagnostics Ltd KRSNAA⚠ unverified31%
Net profit · company comparison
9/9 level · 9/9 change
All-company data · latest reported quarter
CompanyNet profitProfit growthReported
Dr Lal Pathlabs Ltd LALPATHLAB₹170 Cr27%Jun 2026
Metropolis Healthcare Ltd METROPOLIS₹51 Cr76%Mar 2026
Thyrocare Technologies Ltd THYROCARE₹51 Cr34%Jun 2026
Vijaya Diagnostic Centre Ltd VIJAYA₹48 Cr37%Mar 2026
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified₹42 Cr100%Mar 2026
Vimta Labs Ltd VIMTALABS₹22 Cr120%Dec 2024
One Global Service Provider Ltd 514330₹18 Cr64%Mar 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified₹10 Cr22%Mar 2026
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified₹6 Cr-14%Mar 2026
Full 20-quarter history · every available company

Net profit · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

—
—
—
—
—
₹8 Cr
₹5 Cr
₹7 Cr
₹8 Cr
₹9 Cr
₹9 Cr
₹11 Cr
₹15 Cr
₹13 Cr
₹8 Cr
₹13 Cr
₹15 Cr
₹22 Cr
₹10 Cr
—

Dr Lal Pathlabs Ltd · LALPATHLAB

₹95 Cr
₹57 Cr
₹61 Cr
₹58 Cr
₹72 Cr
₹54 Cr
₹57 Cr
₹84 Cr
₹111 Cr
₹82 Cr
₹86 Cr
₹108 Cr
₹131 Cr
₹98 Cr
₹156 Cr
₹134 Cr
₹152 Cr
₹91 Cr
₹132 Cr
₹170 Cr

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

—
—
—
—
—
₹14 Cr
₹19 Cr
₹15 Cr
₹10 Cr
₹13 Cr
₹19 Cr
₹18 Cr
₹20 Cr
₹19 Cr
₹21 Cr
₹21 Cr
₹24 Cr
₹15 Cr
₹42 Cr
—

Metropolis Healthcare Ltd · METROPOLIS

₹58 Cr
₹41 Cr
₹40 Cr
₹33 Cr
₹40 Cr
₹36 Cr
₹33 Cr
₹29 Cr
₹36 Cr
₹27 Cr
₹37 Cr
₹38 Cr
₹47 Cr
₹31 Cr
₹29 Cr
₹45 Cr
₹53 Cr
₹42 Cr
₹51 Cr
—

One Global Service Provider Ltd · 514330

—
—
—
—
₹0 Cr
₹1 Cr
₹0 Cr
₹1 Cr
₹1 Cr
₹1 Cr
₹4 Cr
₹2 Cr
₹2 Cr
₹3 Cr
₹11 Cr
₹10 Cr
₹20 Cr
₹22 Cr
₹18 Cr
—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

—
—
—
—
—
—
—
—
₹8 Cr
₹5 Cr
₹6 Cr
₹8 Cr
₹10 Cr
₹6 Cr
₹7 Cr
₹9 Cr
₹9 Cr
₹7 Cr
₹6 Cr
—

Thyrocare Technologies Ltd · THYROCARE

₹78 Cr
₹22 Cr
₹21 Cr
₹22 Cr
₹15 Cr
₹15 Cr
₹12 Cr
₹17 Cr
₹20 Cr
₹15 Cr
₹17 Cr
₹24 Cr
₹26 Cr
₹19 Cr
₹22 Cr
₹38 Cr
₹48 Cr
₹28 Cr
₹49 Cr
₹51 Cr

Vijaya Diagnostic Centre Ltd · VIJAYA

₹28 Cr
₹25 Cr
₹24 Cr
₹17 Cr
₹23 Cr
₹16 Cr
₹28 Cr
₹26 Cr
₹34 Cr
₹26 Cr
₹34 Cr
₹32 Cr
₹42 Cr
₹35 Cr
₹35 Cr
₹39 Cr
₹43 Cr
₹43 Cr
₹48 Cr
—

Vimta Labs Ltd · VIMTALABS

—
₹12 Cr
₹12 Cr
₹12 Cr
₹13 Cr
₹10 Cr
₹13 Cr
₹12 Cr
₹6 Cr
₹10 Cr
₹12 Cr
₹12 Cr
₹15 Cr
₹22 Cr
—
—
—
—
—
—

Profit growth · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

—
—
—
—
—
—
—
—
—
6.4%
69%
57%
96%
59%
-8.5%
12%
1.1%
66%
22%
—

Dr Lal Pathlabs Ltd · LALPATHLAB

—
—
—
-56%
-24%
-5.3%
-6.6%
45%
54%
52%
51%
29%
18%
20%
81%
24%
16%
-7.1%
-15%
27%

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

—
—
—
—
—
—
—
—
—
-7.1%
0.0%
20%
100%
46%
11%
17%
20%
-21%
100%
—

Metropolis Healthcare Ltd · METROPOLIS

—
—
—
-56%
-31%
-12%
-18%
-12%
-10%
-25%
12%
31%
31%
15%
-22%
18%
13%
35%
76%
—

One Global Service Provider Ltd · 514330

—
—
—
—
—
—
—
—
—
0.0%
—
100%
100%
200%
175%
400%
900%
633%
64%
—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

—
—
—
—
—
—
—
—
—
—
—
—
22%
32%
13%
20%
-13%
21%
-14%
—

Thyrocare Technologies Ltd · THYROCARE

—
—
—
-61%
-81%
-32%
-43%
-23%
33%
0.0%
42%
41%
30%
27%
29%
58%
85%
47%
123%
34%

Vijaya Diagnostic Centre Ltd · VIJAYA

—
—
—
-48%
-18%
-36%
17%
53%
48%
63%
21%
23%
24%
35%
2.9%
22%
2.4%
23%
37%
—

Vimta Labs Ltd · VIMTALABS

—
—
—
—
—
-17%
8.3%
0.0%
-54%
0.0%
-7.7%
0.0%
150%
120%
—
—
—
—
—
—
09 · compare level, then change

Return On Capital Employed

One Global Service Provider Ltd has the highest ROCE among the 9 Diagnostics companies compared here, at 87%. Thyrocare Technologies Ltd is next at 35.4%. The same company also holds the highest ROCE change, at +31 percentage points. 9 of 9 companies report a comparable reading, the latest through Mar 2026.

What the numbers say: One Global Service Provider Ltd leads ROCE at 87%, 51.6 percentage points above Thyrocare Technologies Ltd. One Global Service Provider Ltd has the strongest latest improvement at +31 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.

LeaderOne Global Service Provider Ltd · 87%
Gap145.8% versus #2 · Thyrocare Technologies Ltd
PersistenceNot enough history
Coverage9/9 companies · 101 observations

Investor read: One Global Service Provider Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1One Global Service Provider Ltd 51433087%
2Thyrocare Technologies Ltd THYROCARE35%
3Dr Lal Pathlabs Ltd LALPATHLAB28%
43B Blackbio DX Ltd 3BBLACKBIO⚠ unverified26%
5Vijaya Diagnostic Centre Ltd VIJAYA21%
ROCE changefastest improvers
1One Global Service Provider Ltd 514330+31.0 pp
2Thyrocare Technologies Ltd THYROCARE+8.3 pp
3Metropolis Healthcare Ltd METROPOLIS+2.4 pp
4Vijaya Diagnostic Centre Ltd VIJAYA−0.5 pp
5Dr Lal Pathlabs Ltd LALPATHLAB−1.0 pp
Return on capital · company comparison
9/9 level · 9/9 change

Withheld from this chart: Vimta Labs Ltd (VIMTALABS) — its two data sources disagree by up to 64% on reported income across 13 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.

All-company data · latest reported quarter
CompanyROCEROCE changeReported
Thyrocare Technologies Ltd THYROCARE32%+8.3 ppJun 2026
Dr Lal Pathlabs Ltd LALPATHLAB23%−1.0 ppJun 2026
Vijaya Diagnostic Centre Ltd VIJAYA18%−0.5 ppMar 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified15%−2.6 ppMar 2026
Metropolis Healthcare Ltd METROPOLIS15%+2.4 ppMar 2026
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified14%−2.1 ppMar 2026
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified7.8%−2.6 ppMar 2026
Full 20-quarter history · every available company

ROCE · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

39%
—
25%
—
18%
—
15%
—
12%
19%
14%
23%
18%
28%
18%
26%
15%
26%
15%
—

Dr Lal Pathlabs Ltd · LALPATHLAB

34%
—
25%
—
19%
—
18%
—
21%
26%
24%
29%
24%
30%
24%
31%
24%
29%
23%
—

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

12%
—
12%
—
9.4%
—
8.5%
—
7.7%
10%
7.8%
11%
9.9%
14%
10%
14%
11%
14%
7.8%
—

Metropolis Healthcare Ltd · METROPOLIS

34%
—
23%
—
18%
—
17%
—
15%
15%
15%
16%
16%
17%
12%
15%
13%
16%
15%
—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

—
—
—
—
—
—
—
—
—
—
16%
17%
17%
18%
16%
19%
14%
18%
14%
—

Thyrocare Technologies Ltd · THYROCARE

45%
41%
37%
—
21%
18%
15%
—
16%
18%
17%
20%
21%
25%
24%
30%
31%
37%
32%
—

Vijaya Diagnostic Centre Ltd · VIJAYA

27%
—
23%
—
17%
—
15%
—
17%
22%
18%
22%
19%
23%
18%
23%
17%
22%
18%
—

ROCE change · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

—
—
—
—
−21.0 pp
—
−10.2 pp
—
−5.8 pp
—
−0.4 pp
—
+5.8 pp
+8.4 pp
+3.7 pp
+2.8 pp
−2.3 pp
−1.5 pp
−2.6 pp
—

Dr Lal Pathlabs Ltd · LALPATHLAB

—
—
—
—
−14.8 pp
—
−6.8 pp
—
+1.7 pp
—
+5.7 pp
—
+3.6 pp
+3.7 pp
+0.7 pp
+2.4 pp
−0.5 pp
−0.6 pp
−1.0 pp
—

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

—
—
—
—
−2.8 pp
—
−3.5 pp
—
−1.7 pp
—
−0.7 pp
—
+2.2 pp
+3.4 pp
+2.6 pp
+3.0 pp
+0.9 pp
−0.1 pp
−2.6 pp
—

Metropolis Healthcare Ltd · METROPOLIS

—
—
—
—
−16.2 pp
—
−6.4 pp
—
−2.8 pp
—
−1.6 pp
—
+0.2 pp
+1.7 pp
−2.5 pp
−1.1 pp
−2.9 pp
−1.0 pp
+2.4 pp
—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

—
—
—
—
—
—
—
—
—
—
—
—
—
—
−0.1 pp
+2.2 pp
−2.6 pp
−0.3 pp
−2.1 pp
—

Thyrocare Technologies Ltd · THYROCARE

—
—
—
—
−24.0 pp
−23.1 pp
−22.2 pp
—
−4.8 pp
−0.2 pp
+1.8 pp
—
+5.1 pp
+6.8 pp
+7.1 pp
+9.9 pp
+10.1 pp
+12.8 pp
+8.3 pp
—

Vijaya Diagnostic Centre Ltd · VIJAYA

—
—
—
—
−10.0 pp
—
−8.0 pp
—
−0.7 pp
—
+2.7 pp
—
+2.1 pp
+0.9 pp
+0.2 pp
+0.4 pp
−1.5 pp
−1.2 pp
−0.5 pp
—
10 · compare level, then change

Valuation Against Growth & Quality

Thyrocare Technologies Ltd has the lowest PEG among the 9 Diagnostics companies compared here, at 1.1×. Dr Lal Pathlabs Ltd is next at 1.29×. One Global Service Provider Ltd has the lowest P/E at 15.9×, so level and change sit with different companies. 4 of 9 companies report a comparable reading, the latest through Jun 2026.

What the numbers say: Thyrocare Technologies Ltd has the lowest comparable PEG at 1.1×, 14.7% below Dr Lal Pathlabs Ltd. Only 4 of 9 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.

LeaderThyrocare Technologies Ltd · 1.1×
Gap14.7% versus #2 · Dr Lal Pathlabs Ltd
Persistence0/8 recent comparable periods
Coverage4/9 companies · 33 observations

Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
1Thyrocare Technologies Ltd THYROCARE1.1
2Dr Lal Pathlabs Ltd LALPATHLAB1.3
3Vijaya Diagnostic Centre Ltd VIJAYA1.5
4Metropolis Healthcare Ltd METROPOLIS2.4
P/Elowest P/E
1One Global Service Provider Ltd 51433015.9
2Krsnaa Diagnostics Ltd KRSNAA⚠ unverified16.9
33B Blackbio DX Ltd 3BBLACKBIO⚠ unverified18.3
4Suraksha Diagnostic Ltd SURAKSHA⚠ unverified40.8
5Vimta Labs Ltd VIMTALABS · older report44.8
Valuation · company comparison
4/9 level · 9/9 change
All-company data · latest reported quarter
CompanyPEGP/EReported
Metropolis Healthcare Ltd METROPOLIS2.451.0Mar 2026
Vijaya Diagnostic Centre Ltd VIJAYA1.555.6Mar 2026
Dr Lal Pathlabs Ltd LALPATHLAB1.353.9Jun 2026
Thyrocare Technologies Ltd THYROCARE1.151.2Jun 2026
One Global Service Provider Ltd 514330—20.0Mar 2026
Vimta Labs Ltd VIMTALABS—39.8Dec 2024
Krsnaa Diagnostics Ltd KRSNAA⚠ unverified—22.1Mar 2026
Suraksha Diagnostic Ltd SURAKSHA⚠ unverified—36.9Mar 2026
3B Blackbio DX Ltd 3BBLACKBIO⚠ unverified—17.4Mar 2026
Full 20-quarter history · every available company

PEG · reported quarter history

Dr Lal Pathlabs Ltd · LALPATHLAB

2.8
—
—
—
—
—
—
—
—
3.3
1.6
1.3
1.6
1.9
1.9
1.4
1.5
—
1.3
—

Metropolis Healthcare Ltd · METROPOLIS

—
—
—
3.5
—
—
—
—
—
—
7.7
—
—
4.7
—
—
—
2.4
—
—

Thyrocare Technologies Ltd · THYROCARE

—
—
—
—
—
—
—
—
—
—
1.0
4.8
1.9
2.0
1.2
2.0
1.5
1.1
—
—

Vijaya Diagnostic Centre Ltd · VIJAYA

—
—
—
—
—
—
3.0
—
—
4.5
1.4
1.5
2.1
2.8
3.1
3.6
3.4
5.2
1.5
—

P/E · reported quarter history

3B Blackbio DX Ltd · 3BBLACKBIO⚠ unverified

4.0
8.0
9.3
8.8
13.0
15.6
13.4
12.7
20.9
21.4
20.2
27.6
30.0
39.7
28.9
25.8
23.9
24.4
17.4
—

Dr Lal Pathlabs Ltd · LALPATHLAB

82.2
78.8
59.9
49.0
77.4
76.0
62.6
78.8
79.8
71.3
57.2
64.9
71.6
61.4
49.7
47.9
52.1
44.0
40.5
53.9

Krsnaa Diagnostics Ltd · KRSNAA⚠ unverified

-57.5
58.7
22.4
23.9
25.7
22.7
23.6
29.6
34.2
38.4
34.0
34.0
44.3
40.5
33.6
29.0
32.0
28.0
22.1
—

Metropolis Healthcare Ltd · METROPOLIS

64.1
72.8
45.5
36.4
46.0
43.9
42.8
53.5
54.1
64.5
70.8
79.2
81.7
71.3
54.2
68.2
76.5
72.9
51.0
—

One Global Service Provider Ltd · 514330

5.6
7.4
17.8
32.5
22.5
20.9
13.0
16.6
15.9
10.8
15.6
14.3
16.2
25.9
22.9
14.2
10.7
24.3
20.0
—

Suraksha Diagnostic Ltd · SURAKSHA⚠ unverified

—
—
—
—
—
—
—
—
—
—
—
—
—
2.2
2.4
48.5
43.8
44.2
36.9
—

Thyrocare Technologies Ltd · THYROCARE

39.8
28.8
21.4
18.9
26.1
41.0
31.1
42.5
50.1
52.5
47.6
47.6
55.7
58.5
41.0
57.6
56.0
57.4
40.5
51.2

Vijaya Diagnostic Centre Ltd · VIJAYA

31.2
31.3
23.6
30.8
49.9
49.7
49.4
57.0
54.6
66.8
56.9
63.6
71.8
82.0
72.7
70.4
69.1
69.6
55.6
—

Vimta Labs Ltd · VIMTALABS

19.7
26.2
19.0
17.0
16.2
19.8
14.7
18.8
26.5
20.7
21.7
25.9
26.1
39.8
—
—
—
—
—
—
11 · before the conclusion, check the blind spots

What can make this comparison misleading?

This Diagnostics comparison names 7 specific ways its own evidence can mislead, all listed below. 1 of the 9 companies reports on an older date than the sector's freshest reporters, so its rank is marked stale. 3 draw at least one figure from a second feed with too little overlap to cross-check.

Keep these limits visible

  • A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
  • A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
  • The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
  • An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
  • 1 company has an older fundamental reporting date than the sector’s freshest reporters; its rank carries a stale marker.
  • 3 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
  • 1 company is missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
12 · evidence and freshness

How was this comparison built?

This comparison is built from the reported filings of 9 Diagnostics companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-07-31. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.

FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-07-31 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing4 cross-checked · 4 unverified · 1 withheld, of 9 graded companies.
How a second data feed is admitted, and what happens when it disagrees

A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.

13 · questions investors ask, short speakable answers

Diagnostics company comparison FAQs

These 24 answers restate the Diagnostics comparison above in question form. Every one is computed from the same 9 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-07-31. Nothing here is estimated, and none of it is a recommendation.

Is the Diagnostics sector outperforming NIFTY 500?

Diagnostics has outperformed NIFTY 500 by 10.9% over 52 weeks and 15.5% over 13 weeks. 6 of 9 covered companies beat NIFTY on Mansfield relative strength, while 5 of 9 beat the sector itself.

Which Diagnostics company is largest by revenue?

Dr Lal Pathlabs Ltd leads with revenue of ₹2,892 crore, based on 9 of 9 comparable companies through Jun 2026.

Which Diagnostics company is growing fastest?

One Global Service Provider Ltd has the fastest current revenue growth at 100%, across 9 of 9 comparable companies.

Which Diagnostics company has the strongest 4-Factor Sector Score?

Thyrocare Technologies Ltd ranks first at 77.4/100 with 100% evidence confidence. The score prioritizes research; it is not a buy recommendation.

Which Diagnostics company has the lowest comparable PEG?

Thyrocare Technologies Ltd has the lowest comparable PEG at 1.1, among 4 of 9 companies whose earnings and growth are steady enough for the ratio to mean anything.

How much history does this Diagnostics comparison include?

The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.

How is the 4-Factor Sector Score calculated?

The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.

What is the Nifty Diagnostics index?

The Nifty Diagnostics index tracks India's listed Diagnostics companies as a single basket. This page follows the same 9 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Diagnostics sector rather than to its largest constituent. Figures are as of Jun 2026.

Which are the best Diagnostics stocks in India?

Ranked by this page's four-factor score, Thyrocare Technologies Ltd places first among 9 listed Diagnostics companies, followed by Dr Lal Pathlabs Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.

How many Diagnostics stocks are listed in India?

This comparison covers 9 listed Diagnostics companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.

Which Diagnostics company is the biggest?

Dr Lal Pathlabs Ltd is the largest, with trailing-twelve-month revenue of ₹2,892 crore, ahead of Metropolis Healthcare Ltd at ₹1,646 crore. That covers 9 of 9 companies with comparable reporting through Jun 2026.

Which Diagnostics company has the best profit margins?

Vijaya Diagnostic Centre Ltd has the highest operating margin at 44%, from 9 of 9 comparable companies. Metropolis Healthcare Ltd shows the biggest recent improvement, at +7 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.

Which Diagnostics company makes the most profit?

Dr Lal Pathlabs Ltd earns the most, at ₹545 crore of trailing-twelve-month net profit, from 9 of 9 comparable companies. One Global Service Provider Ltd has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.

Which Diagnostics company earns the highest return on capital?

One Global Service Provider Ltd leads on return on capital employed at 87%, across 9 of 9 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.

Which Diagnostics stock is the cheapest?

On PEG — where a LOWER number is cheaper — Thyrocare Technologies Ltd screens cheapest at 1.1×. Only 4 of 9 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.

Is the Diagnostics sector beating the market?

Diagnostics has outperformed NIFTY 500 by 10.9% over the last 52 weeks and 15.5% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 6 of 9 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.

Which Diagnostics stock has the strongest price momentum?

Thyrocare Technologies Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.

Which Diagnostics company scores highest for research priority?

Thyrocare Technologies Ltd scores 77.4 out of 100 with 100% evidence confidence, from 27.9 points on growth and earnings, 18.1 on capital efficiency, 12 on valuation and 19.4 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.

How many Diagnostics companies does this comparison cover, and over what period?

It compares 9 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.

What is the total market cap of the Diagnostics sector?

The 9 Diagnostics companies on this page carry ₹74,996 crore of combined market value. Dr Lal Pathlabs Ltd is the largest at ₹31,938 crore, about 43% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-05.

What is the Diagnostics sector's P/E ratio?

The median price-to-earnings ratio across the 9 Diagnostics companies on this page is 44.8×, measured on the 9 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-05.

How is the Diagnostics sector performing?

6 of the 9 covered Diagnostics companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 10.9% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-05.

Why are some values on this page blank?

A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.

Is this investment advice?

No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI